These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 16520278)

  • 1. Small molecule, oligonucleotide-based telomerase template inhibition in combination with cytolytic therapy in an in vitro androgen-independent prostate cancer model.
    Canales BK; Li Y; Thompson MG; Gleason JM; Chen Z; Malaeb B; Corey DR; Herbert BS; Shay JW; Koeneman KS
    Urol Oncol; 2006; 24(2):141-51. PubMed ID: 16520278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telomerase enzyme inhibition (TEI) and cytolytic therapy in the management of androgen independent osseous metastatic prostate cancer.
    Li Y; Malaeb BS; Li ZZ; Thompson MG; Chen Z; Corey DR; Hsieh JT; Shay JW; Koeneman KS
    Prostate; 2010 May; 70(6):616-29. PubMed ID: 20043297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy.
    Sowery RD; Hadaschik BA; So AI; Zoubeidi A; Fazli L; Hurtado-Coll A; Gleave ME
    BJU Int; 2008 Aug; 102(3):389-97. PubMed ID: 18336596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human telomerase reverse transcriptase antisense treatment downregulates the viability of prostate cancer cells in vitro.
    Schindler A; Fiedler U; Meye A; Schmidt U; Füssel S; Pilarsky C; Herrmann J; Wirth MP
    Int J Oncol; 2001 Jul; 19(1):25-30. PubMed ID: 11408918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts.
    Dalrymple SL; Becker RE; Isaacs JT
    Prostate; 2007 May; 67(7):790-7. PubMed ID: 17373719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genistein induces cell growth inhibition in prostate cancer through the suppression of telomerase activity.
    Ouchi H; Ishiguro H; Ikeda N; Hori M; Kubota Y; Uemura H
    Int J Urol; 2005 Jan; 12(1):73-80. PubMed ID: 15661057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice.
    Tang Y; Khan MA; Goloubeva O; Lee DI; Jelovac D; Brodie AM; Hussain A
    Clin Cancer Res; 2006 Jan; 12(1):169-74. PubMed ID: 16397039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of telomerase activity and secretion of prostate specific antigen by silibinin in prostate cancer cells.
    Thelen P; Wuttke W; Jarry H; Grzmil M; Ringert RH
    J Urol; 2004 May; 171(5):1934-8. PubMed ID: 15076315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consequences of telomerase inhibition and combination treatments for the proliferation of cancer cells.
    Chen Z; Koeneman KS; Corey DR
    Cancer Res; 2003 Sep; 63(18):5917-25. PubMed ID: 14522918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of cyclooxygenase (COX)-2 expression by Tet-inducible COX-2 antisense cDNA in hormone-refractory prostate cancer significantly slows tumor growth and improves efficacy of chemotherapeutic drugs.
    Dandekar DS; Lokeshwar BL
    Clin Cancer Res; 2004 Dec; 10(23):8037-47. PubMed ID: 15585639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conditionally replicating adenovirus therapy utilizing bone sialoprotein promoter (Ad-BSP-E1a) in an in vivo study of treating androgen-independent intraosseous prostate cancer.
    Li Y; Kacka M; Thompson M; Hsieh JT; Koeneman KS
    Urol Oncol; 2011; 29(6):624-33. PubMed ID: 19963408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct and distant antitumor effects of a telomerase-selective oncolytic adenoviral agent, OBP-301, in a mouse prostate cancer model.
    Huang P; Watanabe M; Kaku H; Kashiwakura Y; Chen J; Saika T; Nasu Y; Fujiwara T; Urata Y; Kumon H
    Cancer Gene Ther; 2008 May; 15(5):315-22. PubMed ID: 18274558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3,3'-Diindolylmethane enhances taxotere-induced apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation.
    Rahman KM; Banerjee S; Ali S; Ahmad A; Wang Z; Kong D; Sakr WA
    Cancer Res; 2009 May; 69(10):4468-75. PubMed ID: 19435906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer.
    Narita S; So A; Ettinger S; Hayashi N; Muramaki M; Fazli L; Kim Y; Gleave ME
    Clin Cancer Res; 2008 Sep; 14(18):5769-77. PubMed ID: 18794086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer stem cells, telomerase biology, epigenetic modifiers, and molecular systemic therapy for the androgen-independent lethal phenotype.
    Koeneman KS
    Urol Oncol; 2006; 24(2):119-21. PubMed ID: 16520275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conditionally replicating adenovirus-mediated gene therapy in bladder cancer: an orthotopic in vivo model.
    Melquist JJ; Kacka M; Li Y; Malaeb BS; Elmore J; Baseman AG; Hsieh JT; Koeneman KS
    Urol Oncol; 2006; 24(4):362-71. PubMed ID: 16818192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis.
    Matsubara S; Wada Y; Gardner TA; Egawa M; Park MS; Hsieh CL; Zhau HE; Kao C; Kamidono S; Gillenwater JY; Chung LW
    Cancer Res; 2001 Aug; 61(16):6012-9. PubMed ID: 11507044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.
    Miyake H; Chi KN; Gleave ME
    Clin Cancer Res; 2000 May; 6(5):1655-63. PubMed ID: 10815883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA component.
    Kondo Y; Koga S; Komata T; Kondo S
    Oncogene; 2000 Apr; 19(18):2205-11. PubMed ID: 10822370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New approaches in hormone refractory prostate cancer.
    Sonpavde G; Hutson TE
    Am J Clin Oncol; 2006 Apr; 29(2):196-201. PubMed ID: 16601442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.